Phosphorylation-Dependent Control of Pc2 SUMO E3 Ligase Activity by Its Substrate Protein HIPK2

Molecular Cell

Volumn 24, Issue 1, 2006, Pages 77-89

  Roscic, Ana ^a   Möller, Andreas ^b   Calzado, Marco A ^a   Renner, Florian ^a   Wimmer, Verena C ^c   Gresko, Ekaterina ^d   Lüdi, Katharina Schmid ^e   Schmitz, M  Lienhard ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c MAX PLANCK INSTITUTE FOR MEDICAL RESEARCH   (Germany)

^d FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

DNA; PROTEINS

Indexed keywords

DNA; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; SUMO PROTEIN; THREONINE; UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; AUTOREGULATION; BINDING SITE; CELL FUNCTION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEEDBACK SYSTEM; GENE SILENCING; NONHUMAN; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION;

CARRIER PROTEINS; CELL LINE; DNA DAMAGE; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SUMO-1 PROTEIN; UBIQUITIN-PROTEIN LIGASES;

EID: 33749058094     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2006.08.004     Document Type: Article

References (52)

1. Bossis G., and Melchior F. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Mol. Cell 21 (2006) 349-357
2. Boyer-Guittaut M., Birsoy K., Potel C., Elliott G., Jaffray E., Desterro J.M., Hay R.T., and Oelgeschlager T. SUMO-1 modification of human transcription factor (TF) IID complex subunits: inhibition of TFIID promoter-binding activity through SUMO-1 modification of hsTAF5. J. Biol. Chem. 280 (2005) 9937-9945
3. Bracken A.P., Dietrich N., Pasini D., Hansen K.H., and Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20 (2006) 1123-1136
4. Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P., Jones R.S., and Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298 (2002) 1039-1043
5. Choi C.Y., Kim Y.H., Kwon H.J., and Kim Y. The homeodomain protein NK-3 recruits Groucho and a histone deacetylase complex to repress transcription. J. Biol. Chem. 274 (1999) 33194-33197
6. Di Stefano V., Rinaldo C., Sacchi A., Soddu S., and D'Orazi G. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp. Cell Res. 293 (2004) 311-320
7. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4 (2002) 11-19
8. Francis N.J., and Kingston R.E. Mechanisms of transcriptional memory. Nat. Rev. Mol. Cell Biol. 2 (2001) 409-421
9. Gao M., and Karin M. Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. Mol. Cell 19 (2005) 581-593
10. Gentile M., Latonen L., and Laiho M. Cell cycle arrest and apoptosis provoked by UV radiation-induced DNA damage are transcriptionally highly divergent responses. Nucleic Acids Res. 31 (2003) 4779-4790
11. Gill G. Something about SUMO inhibits transcription. Curr. Opin. Genet. Dev. 15 (2005) 536-541
12. Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., Scheffner M., and Del Sal G. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 18 (1999) 6462-6471
13. Gresko E., Moller A., Roscic A., and Schmitz M.L. Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability. Biochem. Biophys. Res. Commun. 329 (2005) 1293-1299
14. Gresko E., Roscic A., Ritterhoff S., Vichalkovski A., del Sal G., and Schmitz M.L. Autoregulatory control of the p53 response by caspase-mediated processing of HIPK2. EMBO J. 25 (2006) 1883-1894
15. Gross M., Liu B., Tan J., French F.S., Carey M., and Shuai K. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 20 (2001) 3880-3887
16. Harada J., Kokura K., Kanei-Ishii C., Nomura T., Khan M.M., Kim Y., and Ishii S. Requirement of the co-repressor homeodomain-interacting protein kinase 2 for ski-mediated inhibition of bone morphogenetic protein-induced transcriptional activation. J. Biol. Chem. 278 (2003) 38998-39005
17. Hay R.T. SUMO: a history of modification. Mol. Cell 18 (2005) 1-12
18. Hietakangas V., Anckar J., Blomster H.A., Fujimoto M., Palvimo J.J., Nakai A., and Sistonen L. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc. Natl. Acad. Sci. USA 103 (2006) 45-50
19. Hofmann T.G., Mincheva A., Lichter P., Droge W., and Schmitz M.L. Human homeodomain-interacting protein kinase-2 (HIPK2) is a member of the DYRK family of protein kinases and maps to chromosome 7q32-q34. Biochimie 82 (2000) 1123-1127
20. Hofmann T.G., Moller A., Sirma H., Zentgraf H., Taya Y., Droge W., Will H., and Schmitz M.L. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4 (2002) 1-10
21. Hofmann T.G., Stollberg N., Schmitz M.L., and Will H. HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res. 63 (2003) 8271-8277
22. Hofmann T.G., Jaffray E., Stollberg N., Hay R.T., and Will H. Regulation of homeodomain-interacting protein kinase 2 (HIPK2) effector function through dynamic small ubiquitin-related modifier-1 (SUMO-1) modification. J. Biol. Chem. 280 (2005) 29224-29232
23. Johnson E.S. Protein modification by SUMO. Annu. Rev. Biochem. 73 (2004) 355-382
24. Kagey M.H., Melhuish T.A., and Wotton D. The polycomb protein Pc2 is a SUMO E3. Cell 113 (2003) 127-137
25. Kagey M.H., Melhuish T.A., Powers S.E., and Wotton D. Multiple activities contribute to Pc2 E3 function. EMBO J. 24 (2005) 108-119
26. Kim Y.H., Choi C.Y., Lee S.J., Conti M.A., and Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J. Biol. Chem. 273 (1998) 25875-25879
27. Kim Y.H., Choi C.Y., and Kim Y. Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1. Proc. Natl. Acad. Sci. USA 96 (1999) 12350-12355
28. Lee B.H., Yoshimatsu K., Maeda A., Ochiai K., Morimatsu M., Araki K., Ogino M., Morikawa S., and Arikawa J. Association of the nucleocapsid protein of the Seoul and Hantaan hantaviruses with small ubiquitin-like modifier-1-related molecules. Virus Res. 98 (2003) 83-91
29. Lund A.H., and van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr. Opin. Cell Biol. 16 (2004) 239-246
30. Lydall D., and Whitehall S. Chromatin and the DNA damage response. DNA Repair (Amst.) 4 (2005) 1195-1207
31. Melchior F., Schergaut M., and Pichler A. SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28 (2003) 612-618
32. Moller A., Sirma H., Hofmann T.G., Rueffer S., Klimczak E., Droge W., Will H., and Schmitz M.L. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res. 63 (2003) 4310-4314
33. Muller S., Matunis M.J., and Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17 (1998) 61-70
34. Muratani M., Gerlich D., Janicki S.M., Gebhard M., Eils R., and Spector D.L. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nat. Cell Biol. 4 (2002) 106-110
35. Okuma T., Honda R., Ichikawa G., Tsumagari N., and Yasuda H. In vitro SUMO-1 modification requires two enzymatic steps, E1 and E2. Biochem. Biophys. Res. Commun. 254 (1999) 693-698
36. Orlando V. Polycomb, epigenomes, and control of cell identity. Cell 112 (2003) 599-606
37. Otte A.P., and Kwaks T.H. Gene repression by Polycomb group protein complexes: a distinct complex for every occasion?. Curr. Opin. Genet. Dev. 13 (2003) 448-454
38. Pichler A., Gast A., Seeler J.S., Dejean A., and Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 108 (2002) 109-120
39. Pierantoni G.M., Fedele M., Pentimalli F., Benvenuto G., Pero R., Viglietto G., Santoro M., Chiariotti L., and Fusco A. High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 20 (2001) 6132-6141
40. Plaisance S., Vanden Berghe W., Boone E., Fiers W., and Haegeman G. Recombination signal sequence binding protein Jkappa is constitutively bound to the NF-kappaB site of the interleukin-6 promoter and acts as a negative regulatory factor. Mol. Cell. Biol. 17 (1997) 3733-3743
41. Ringrose L., and Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu. Rev. Genet. 38 (2004) 413-443
42. Sachdev S., Bruhn L., Sieber H., Pichler A., Melchior F., and Grosschedl R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 15 (2001) 3088-3103
43. Saurin A.J., Shiels C., Williamson J., Satijn D.P., Otte A.P., Sheer D., and Freemont P.S. The human polycomb group complex associates with pericentromeric heterochromatin to form a novel nuclear domain. J. Cell Biol. 142 (1998) 887-898
44. Seeler J.S., and Dejean A. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell Biol. 4 (2003) 690-699
45. Sewalt R.G., van der Vlag J., Gunster M.J., Hamer K.M., den Blaauwen J.L., Satijn D.P., Hendrix T., van Driel R., and Otte A.P. Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol. Cell. Biol. 18 (1998) 3586-3595
46. Steffan J.S., Agrawal N., Pallos J., Rockabrand E., Trotman L.C., Slepko N., Illes K., Lukacsovich T., Zhu Y.Z., Cattaneo E., et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 304 (2004) 100-104
47. Sung K.S., Go Y.Y., Ahn J.H., Kim Y.H., Kim Y., and Choi C.Y. Differential interactions of the homeodomain-interacting protein kinase 2 (HIPK2) by phosphorylation-dependent sumoylation. FEBS Lett. 579 (2005) 3001-3008
48. Ulrich H.D. Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. Trends Cell Biol. 15 (2005) 525-532
49. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439 (2006) 871-874
50. Wiggins A.K., Wei G., Doxakis E., Wong C., Tang A.A., Zang K., Luo E.J., Neve R.L., Reichardt L.F., and Huang E.J. Interaction of Brn3a and HIPK2 mediates transcriptional repression of sensory neuron survival. J. Cell Biol. 167 (2004) 257-267
51. Zhang Q., Yoshimatsu Y., Hildebrand J., Frisch S.M., and Goodman R.H. Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell 115 (2003) 177-186
52. Zhang H., Smolen G.A., Palmer R., Christoforou A., van den Heuvel S., and Haber D.A. SUMO modification is required for in vivo Hox gene regulation by the Caenorhabditis elegans Polycomb group protein SOP-2. Nat. Genet. 36 (2004) 507-511